Jose Gonzalo Zavaleta, M.D.; Denial of Application, 64128-64131 [2012-25576]
Download as PDF
64128
Federal Register / Vol. 77, No. 202 / Thursday, October 18, 2012 / Notices
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Wireless Industrial
Technology Konsortium Inc.
Notice is hereby given that, on
September 25, 2012, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Wireless Industrial Technology
Konsortium Inc. (‘‘WITEK’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Nivis LLC, Atlanta, GA, has been added
as a party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and WITEK
intends to file additional written
notifications disclosing all changes in
membership.
On August 8, 2008, WITEK filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on September 18, 2008 (73 FR
54170).
The last notification was filed with
the Department on November 2, 2010. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on December 17, 2010 (75 FR
79025).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
Advanced Media Workflow Association,
Inc. has filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Apple, Cupertino, CA;
Tedial, Campanillas, SPAIN; Harry Plate
(individual member), Snohomish, WA;
and Robert Rutherford (individual
member), Lidcombe, Australia, have
been added as parties to this venture.
Also, Automatic Duck, Snohomish,
WA; Dark Matter, Epsom, Surrey,
United Kingdom; Oracle America,
Redwood Shores, CA; SeaChange
International, Acton, MA; and Brooks
Harris (individual member), Marina del
Rey, CA, have withdrawn as parties to
this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and Advanced
Media Workflow Association, Inc.
intends to file additional written
notifications disclosing all changes in
membership.
On March 28, 2000, Advanced Media
Workflow Association, Inc. filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on June 29, 2000 (65 FR 40127).
The last notification was filed with
the Department on July 3, 2012. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on July 25, 2012 (77 FR 43614).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2012–25694 Filed 10–17–12; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Antitrust Division
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993; Advanced Media Workflow
Association, Inc.
Notice is hereby given that, on
September 24, 2012, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
VerDate Mar<15>2010
18:15 Oct 17, 2012
Jkt 229001
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Network Centric
Operations Industry Consortium, Inc.
Notice is hereby given that, on
September 25, 2012, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Network Centric Operations Industry
Consortium, Inc. (‘‘NCOIC’’) has filed
written notifications simultaneously
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2012–25691 Filed 10–17–12; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Jose Gonzalo Zavaleta, M.D.; Denial of
Application
[FR Doc. 2012–25689 Filed 10–17–12; 8:45 am]
BILLING CODE P
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Office of the Assistant Secretary for
Networks & Information Integration/
Department of Defense Chief
Information Officer, Washington, DC;
CACI International, Inc., Arlington, VA;
Federal Aviation Administration,
Washington, DC; GBL Systems,
Camarillo, CA; L–3 Communications,
New York, NY; Luciad, Leuven,
BELGIUM; and Mosaic ATM, Leesburg,
VA, have withdrawn as parties to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and NCOIC
intends to file additional written
notifications disclosing all changes in
membership.
On November 19, 2004, NCOIC filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on February 2, 2005 (70
FR 5486).
The last notification was filed with
the Department on May 9, 2012. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on June 8, 2012 (77 FR 34066).
On March 2, 2011, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause (Order) to Jose Gonzalo
Zavaleta, M.D. (Applicant), of
Alexandria, Louisiana (La.). The Order
proposed the denial of Applicant’s
pending applications for DEA
Certificates of Registration as a
practitioner, which he filed on April 19,
2010 (Control Number W10020882C)
and on December 9, 2010 (Control
Number W10078290C), for the
registered location of 1217 Willow Glen
E:\FR\FM\18OCN1.SGM
18OCN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 202 / Thursday, October 18, 2012 / Notices
River Road, Alexandria, La., on the
ground that his registration would be
‘‘inconsistent with the public interest.’’
Order at 1 (citing 21 U.S.C. 823(f)).
The Show Cause Order incorporated
by reference the allegations of a
previous Show Cause Order which had
been issued on February 23, 2009; a
copy of the latter was attached to the
second Show Cause Order. Id. at 1–2.
The first Show Cause Order had alleged
that Applicant voluntarily surrendered
his DEA Certificate of Registration,
BZ5998250, on March 26, 2008, after
being charged with six counts of
prescribing controlled substances
beyond authority and accepted medical
treatment, in violation of La. Rev. Stat.
Ann. § 40:971(C)(1)(2008) (effective
Aug. 15, 2006). Id. The first Order
further alleged that Applicant
prescribed controlled substances to
undercover agents with ‘‘cursory or no
medical examinations, and without a
legitimate medical purpose in violation
of 21 U.S.C. § 841(a)(1),’’ including a
total of 75 dosage units of hydrocodone
(including Lortab and/or Lorcet), which
are schedule III narcotics; 20 dosage
units of Xanax, a schedule IV controlled
substance; and six ounces of Phenergan
with codeine, a schedule V narcotic
cough syrup. Id. Finally, the first Order
alleged ‘‘[Applicant] facilitated the
undercover officers’ procurement of
drugs by fraudulent means’’ when he
advised them to ‘‘provide false medical
information’’ to justify ‘‘illegitimate
prescriptions.’’ Id. at 2.
In addition to these allegations, the
Second Show Cause Order alleged that
on June 24, 2010, Applicant had entered
into a consent agreement with the
Louisiana State Board of Medical
Examiners which had found ‘‘that
reasonable cause existed for
recommending that a formal
Administrative Complaint be filed
against [him], charging [him] with
violation of the Louisiana Medical
Practice Act.’’ Show Cause Order at 2.
The Second Show Cause Order further
alleged that ‘‘[t]o avoid the filing of a
formal Administrative Complaint,
[Applicant] entered into a consent order
with the Board * * * in which [he]
accepted a public reprimand and
various conditions [were] place upon
[his] medical license.’’
On March 7, 2011, the Second Show
Cause Order, which also notified
Applicant of his right to either request
a hearing on the allegations or to submit
a written statement in lieu of a hearing,
the procedures for doing so, and the
consequence if he failed to do either,
was served on Applicant by certified
mail addressed to him at the address
listed on his second and third
VerDate Mar<15>2010
18:15 Oct 17, 2012
Jkt 229001
applications. Id. at 2 (citing 21 CFR
1316.47; 21 CFR 1301.43). Since service
of the Second Order, more than thirty
days have now passed and neither
Applicant, nor anyone purporting to
represent him, has either requested a
hearing or submitted a written statement
in lieu of a hearing. See 21 CFR
1301.43(b)–(d). Accordingly, I find that
Applicant has waived his rights to a
hearing or to submit a written statement.
Id. 1301.43(d). I therefore issue this
Decision and Final Order without a
hearing based on relevant material
contained in the investigative record
submitted by the Government. I make
the following findings.
Findings
On July 27, 2011, I issued a Decision
and Final Order denying Respondent’s
application which he filed on July 28,
2008 and which was the subject of the
first Show Cause Order. See Jose
Gonzalo Zavaleta, M.D., 76 FR 49506
(Aug. 10, 2011). Therein, I made
extensive findings that are res judicata
in this proceeding.
Applicant was previously the holder
of DEA Certificate of Registration,
BZ5998250, which authorized him to
dispense controlled substances in
schedules II through V as a practitioner
at the registered location of 5629
Jackson Street Ext., Alexandria,
Louisiana. 76 FR 49506. However, on
March 26, 2008, concurrent with
Applicant’s arrest on state drug charges
(the circumstances of which are set forth
below), he voluntarily surrendered his
registration. Id. Applicant’s registration
was then retired by DEA on March 27,
2008. Id.
On July 28, 2008, Applicant applied
for a new DEA registration as a
practitioner in schedules IV and V; this
application was denied by my Order of
August 10, 2011. Id. On April 19, 2010,
Applicant filed a second application for
a practitioner’s registration, seeking
authority to handle controlled
substances in schedules II thorugh V at
the registered location of Rapides
Primary Health Care Center, 1217
Willow Glenn River Rd., Alexandria, La.
71302. GX 6, at 1. On his application,
Respondent stated that ‘‘the DA made
me an offer for a program called PTI and
no DEA license for two years. Now, I
have completed my part of the deal,
meaning I completed two years without
[a] DEA license, and now I want my
unrestricted DEA license back.’’ Id. On
December 9, 2010, Respondent filed a
third application; this application was
also for the registered location of the
Rapides Primary Health Care Center. GX
7.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
64129
Applicant first came to the attention
of law enforcement on January 17, 2008,
when Louisiana State Police received a
call from a pharmacist that he had
authorized prescriptions for ‘‘excessive
amounts of name brand narcotics with
no generic substitutions allowed.’’ 76
FR at 49506. Upon receipt of this
information, an undercover state trooper
(UC1) visited Applicant’s clinic with
audio/video recording equipment on
January 23, 2008. Id. When Applicant
asked UC1 ‘‘why he was there,’’ UC1
responded by requesting
‘‘[h]ydrocodone pain pills.’’ Id. UC1
‘‘initially denied that he was in pain
but, after negotiating with [Applicant],
he agreed to falsely state that he was
suffering from a sexually transmitted
disease,’’ and Applicant recorded this
false information in UC1’s medical file.
Id. Then, Applicant, without any
physical examination to verify the claim
of illness or symptoms, wrote
prescriptions for 15 Lortab 1 pills and an
antibiotic. Id. The undercover agent
paid $100 for the visit. Id.
Five days later, on January 28, 2008,
UC1 returned to Applicant’s clinic
seeking additional ‘‘pain pills.’’ Id.
However, Applicant denied his request
for more pain pills ‘‘because ‘big
brother’ was watching him.’’ Id.
Thereafter, on January 30, February 8,
and February 28, 2008, a second state
trooper (UC2) visited Applicant’s clinic
in an undercover capacity, while
equipped with an audio/video recording
device. Id. At UC2’s first visit,
Applicant issued her a prescription for
hydrocodone,2 notwithstanding UC2’s
‘‘initially den[ying] she was in pain’’
and ‘‘later stat[ing] she was in pain in
order to obtain a prescription for
hydrocodone.’’ Id. At her second visit
on February 8, Applicant provided
prescriptions for hydrocodone and
Phenergan with codeine,3 the latter
being a cough syrup, ‘‘even though she
had no cough or congestion and
exhibited no such symptoms.’’ Id. On
UC2’s third visit, she requested and
obtained from Applicant prescriptions
for hydrocodone and Xanax.4 Id. To
justify issuing the prescriptions,
Applicant ‘‘coached’’ UC2 about what to
say and recorded the coached
statements in her medical file. Id. At the
1 Lortab, which is a combination drug containing
hydrocodone and acetaminophen, is a schedule III
controlled substance. 21 CFR 1308.13(e)(iv).
2 Hydrocodone is typically combined with
acetaminophen. In this formulation, it is a schedule
III controlled substance. 21 CFR 1308.13(e)(iv).
3 Phenergan with codeine cough syrup consists of
a combination of promethazine and codeine; it is
a schedule V controlled substance. 21 CFR
1308.15(c).
4 Xanax (alprazolam) is a schedule IV controlled
substance. 21 CFR 1308.14(c)(1).
E:\FR\FM\18OCN1.SGM
18OCN1
64130
Federal Register / Vol. 77, No. 202 / Thursday, October 18, 2012 / Notices
undercover visits, Applicant never
‘‘require[d] any medical records nor did
he conduct any physical examinations.’’
Id.
On March 20, 2008, after a state court
judge issued a warrant for Applicant’s
arrest, Louisiana State Police alerted
DEA to the investigation and pending
arrest. Id. Thereafter, on March 26,
2008, Applicant was arrested and
charged with ‘‘six counts of prescribing
beyond authority and accepted medical
treatment, a violation of Louisiana
Revised Statute 40:971C(1).’’ Id. Based
on Applicant’s arrest, a DEA Diversion
Investigator asked for the voluntary
surrender of his DEA registration;
Applicant agreed and signed a DEA–
104, Voluntary Surrender of Controlled
Substance Privileges.5 Id. at 49506–07.
Respondent has presented no
evidence that he acknowledges his
misconduct and accepts responsibility
for it.
Discussion
Section 303(f) of the Controlled
Substances Act (CSA) provides that an
application for a practitioner’s
registration may be denied upon a
determination ‘‘that the issuance of such
registration would be inconsistent with
the public interest.’’ 21 U.S.C. 823(f). In
making the public interest
determination in the case of a
practitioner, Congress directed that the
following factors be considered:
mstockstill on DSK4VPTVN1PROD with NOTICES
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The applicant’s experience in
dispensing * * * controlled substances.
(3) The applicant’s conviction record under
Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
5 As part of the record in this matter, the
Government submitted a copy of the Consent Order
applicant entered into with the Louisiana State
Board of Medical Examiners. GX 5. While therein,
Applicant ‘‘acknowledge[d] that the reported
information could provide the Investigating Officer
with probable cause to pursue formal
administrative proceedings against him for
violation of the [Louisiana Medical Practice] Act,’’
Applicant did not admit to any of the allegations.
Id. at 2. Accordingly, I do not rely on the Consent
Order to make any findings regarding violations of
federal law by the Applicant in prescribing to
undercover agents.
However, I find that Respondent had a full and
fair opportunity to litigate the allegations of the first
DEA Show Cause Order, even if he did not avail
himself of it. See Alan H. Olefsky, 76 FR 20025,
20031 (2011); Robert L. Dougherty 76 FR 16823,
16830 (2011). Accordingly, those findings are res
judicata in this proceeding. Olefsky, 76 FR at
20031; Dougherty, 76 FR at 16830.
VerDate Mar<15>2010
18:15 Oct 17, 2012
Jkt 229001
Id.
‘‘[T]hese factors are considered in the
disjunctive.’’ Robert A. Leslie, 68 FR
15227, 15230 (2003). I may rely on any
one or a combination of factors and may
give each factor the weight I deem
appropriate in determining whether
* * * to deny an application. Id.
Moreover, I am ‘‘not required to make
findings as to all of the factors.’’ Hoxie
v. DEA, 419 F.3d 477, 482 (6th Cir.
2005) (citing Morall v. DEA, 412 F.3d
165, 173–74 (D.C. Cir. 2005)).
In this matter, while I have
considered all of the factors, I conclude
that it is not necessary to make findings
with respect to factors one (the
recommendation of the state licensing
board), three (applicant’s conviction
record) and five (such other conduct
which may threaten public health and
safety). Having previously found that
Applicant has committed acts which
render his registration ‘‘inconsistent
with the public interest,’’ 76 FR at
49507 (quoting 21 U.S.C. 823(f),
824(a)(4)), and Applicant having failed
to present any evidence to rebut this
conclusion, I will order that his pending
applications for registration be denied.
Factors Two and Four—Applicant’s
Experience in Dispensing Controlled
Substances and Compliance With
Applicable Laws Related to Controlled
Substances
Under a longstanding DEA regulation,
a prescription for a controlled substance
is not ‘‘effective’’ unless it is ‘‘issued for
a legitimate medical purpose by an
individual practitioner acting in the
usual course of his professional
practice.’’ 21 CFR 1306.04(a). This
regulation further provides that ‘‘an
order purporting to be a prescription
issued not in the usual course of
professional treatment * * * is not a
prescription within the meaning and
intent of [21 U.S.C. 829] and * * * the
person issuing it, shall be subject to the
penalties provided for violations of the
provisions of law related to controlled
substances.’’ Id.; see also La. Rev. Stat.
Ann. § 40:961(33) (2008) (effective Aug.
15, 2004); 6 La. Rev. Stat. Ann.
§ 40:1238.2(A) (2008) (effective Aug. 15,
2006).7
6 Louisiana law defines the term ‘‘prescription’’ to
mean ‘‘a written request for a drug * * * issued by
a licensed physician * * * for a legitimate medical
purpose, for the purpose of correcting a physical,
mental, or bodily ailment, and acting in good faith
in the usual course of his professional practice.’’ La.
Rev. Stat. Ann. § 40.961(33).
7 This statute provides that:
A prescription, in order to be effective in
legalizing the possession of legend drugs, shall be
issued for a legitimate medical purpose by one
authorized to prescribe the use of such legend
drugs. An order purporting to be a prescription
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
As the Supreme Court recently
explained, ‘‘the [CSA’s] prescription
requirement * * * ensures patients use
controlled substances under the
supervision of a doctor so as to prevent
addiction and recreational abuse. As a
corollary, [it] also bars doctors from
peddling to patients who crave the
drugs for those prohibited uses.’’
Gonzales v. Oregon, 546 U.S. 243, 274
(2006) (citing United States v. Moore,
423 U.S. 122, 135, 143 (1975)); see also
La. Rev. Stat. Ann. § 40:1238.2(A) (2008)
(effective Aug. 15, 2006).
Under the CSA, it is fundamental that
a practitioner must establish and
maintain a bonafide doctor-patient
relationship in order to act ‘‘in the usual
course of * * * professional practice’’
and to issue a prescription for a
‘‘legitimate medical purpose.’’ Laurence
T. McKinney, 73 FR 43260, 43265 n.22
(2008); see also Moore, 423 U.S. at 142–
43 (noting that evidence established that
physician ‘‘exceeded the bounds of
‘professional practice,’’’ when ‘‘he gave
inadequate physical examinations or
none at all,’’ ‘‘ignored the results of the
tests he did make,’’ and ‘‘took no
precautions against * * * misuse and
diversion’’). The CSA generally looks to
state law to determine whether a doctor
and patient have established a bonafide
doctor-patient relationship. See Kamir
Garces-Mejias, 72 FR 54931, 54935
(2007); United Prescription Services,
Inc., 72 FR 50397, 50407 (2007); but see
21 U.S.C. § 829(e)(2)(B) (providing
federal standard for prescribing over the
internet).
Under the regulation of the Louisiana
Board of Medical Examiners, in the
treatment of ‘‘intractable pain * * * a
physician shall comply’’ with the
Louisiana Pain Rules, including the
requirements that a physician perform
an ‘‘[e]valuation of the [p]atient’’ and
make a ‘‘[m]edical [d]iagnosis.’’ La.
Admin. Code tit. 46:XLV.6921(A)
(2008). ‘‘Evaluation of the patient shall
initially include relevant medical, pain,
alcohol and substance abuse histories,
an assessment of the impact of pain on
the patient’s physical and psychological
functions, a review of previous
diagnostics studies, previously utilized
therapies, an assessment of coexisting
illnesses, diseases, or conditions, and an
appropriate physical examination.’’ Id.
issued to a drug abuser or habitual user of legend
drugs, not in the course of professional treatment,
is not a prescription within the meaning and intent
of this Section. Any person who knows or should
know that he or she is filling such a prescription
or order to a drug abuser or habitual user of legend
drugs, as well as the person issuing the
prescription, may be charged with a violation of
this Section.
La. Rev. Stat. Ann. § 40:1238.2(A).
E:\FR\FM\18OCN1.SGM
18OCN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 202 / Thursday, October 18, 2012 / Notices
(emphasis added); see also Armstrong v.
La. State Bd. of Med. Examiners, 868 So.
2d 830, 840 (La.App. 4 Cir. Feb. 18,
2004) (upholding two year suspension
of physician’s license; noting that when
prescribing controlled substances for
relief of non-malignant pain is
‘‘unaccompanied by appropriate testing,
diagnosis, oversight and monitoring
* * * the physician falls below
generally accepted standards of care’’);
Pastorek v. La. State Bd. of Med.
Examiners, 4 So. 3d 833 (La.App. 4 Cir.
Dec. 17, 2008). The Board’s rules further
require that a ‘‘medical diagnosis * * *
be established and fully documented in
the patient’s medical record.’’ La.
Admin. Code tit. 46:XLV.6921(A)(2)
(2008).
Louisiana law also prohibits a
physician from ‘‘[a]ssist[ing] a patient or
any other person in obtaining a
controlled dangerous substance through
misrepresentation, fraud, forgery,
deception, or subterfuge.’’ La. Rev. Stat.
Ann. § 40:971.2 (2008) (effective Aug.
15, 2005). It is also unlawful for a
physician to ‘‘prescribe * * * legally
controlled substances beyond his
respective prescribing authority or for a
purpose other than accepted medical
treatment of disease, condition, or
illness. Id., at § 40:971(C)(1) (2008)
(effective Sept. 9, 1988).
As found in my Decision and Order
of July 27, 2011, on four occasions,
Applicant prescribed drugs containing
hydrocodone (including Lortab and/or
Lorcet), which are schedule III
narcotics; Xanax, a schedule IV
controlled substance; and Phenergan
with codeine, a schedule V narcotic
cough syrup; to Louisiana State
Troopers acting in undercover
capacities. See 76 FR at 49508. Notably,
Applicant issued these prescriptions
without conducting a physical
examination at any of the visits and the
undercover agents received these
prescriptions even though they did not
demonstrate conditions or symptoms
that would justify the prescriptions. Id.
Moreover, both undercover agents
initially denied they were in pain, but
Applicant assisted the agents in
obtaining controlled substances by
encouraging them to make false
statements. See id. For example, while
he denied being in pain, UC1 asked
Applicant for ‘‘[h]ydrocodone pain
pills,’’ and then ‘‘negotiate[ed]’’ with
Applicant to ‘‘falsely state’’ he had a
sexually transmitted disease. Id.
Likewise, Applicant also ‘‘coached’’ the
second undercover agent on what to say
to ‘‘justify issuing the prescriptions and
wrote her coached statements in a
medical file.’’ Id. Therefore, Applicant
failed to establish a physician-patient
VerDate Mar<15>2010
18:15 Oct 17, 2012
Jkt 229001
relationship, lacked a legitimate medical
purpose, and acted outside of the usual
course of professional practice in
prescribing controlled substances to the
undercover agents and thus violated
Federal law. See id. (citing 21 CFR
1306.04(a); 21 U.S.C. 841(a)(1); see also
Louisiana v. Moody, 393 So. 2d 1212,
1215 (La. 1981) (holding that physician
furnished prescriptions for ‘‘other than
a legitimate medical purpose’’ based on
evidence showing that prescriptions
were issued in response to specific
requests of patients and physician did
not conduct physical examinations or
take medical histories)).
I therefore hold again that granting
Applicant’s applications for a new
registration ‘‘would be inconsistent with
the public interest.8’’ 21 U.S.C. 823(f).
Accordingly, I will order that
Applicant’s pending applications be
denied.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 28 CFR 0.100(b),
I order that the applications (Control
Numbers W10020882C and
W10078290C) of Jose Gonzalo Zavaleta,
M.D., for a DEA Certificate of
Registration as a practitioner be, and
they hereby are, denied. This order is
effective November 19, 2012.
Dated: October 8, 2012.
Michele M. Leonhart,
Administrator.
[FR Doc. 2012–25576 Filed 10–17–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 11–34]
Zvi H. Perper, M.D., Decision and Order
On July 19, 2011, Administrative Law
Judge (ALJ) Gail A. Randall issued the
attached recommended decision. The
8 As found above, Applicant stated in his second
application that ‘‘the DA made me an offer for a
program called PTI and no DEA license for two
years,’’ and that because he has ‘‘completed two
years without [a] DEA license,’’ he ‘‘want[s] [his]
unrestricted DEA license back.’’ GX 6. Respondent
has presented no evidence that any DEA official
agreed to the deal he made with the district
attorney, and in any event, a state official has no
authority to bind this Agency. See Edmund Chein,
72 FR 6580, 6590 (2007) (Congress granted the
authority to determine whether a registration ‘‘is
consistent with the public interest’’ to ‘‘the
Attorney General of the United States, and that
authority has been delegated solely to the officials
of [DEA]. State officials therefore lack authority to
resolve a matter pending before the Drug
Enforcement Administration’’ and cannot bind this
Agency.) (citing 21 U.S.C. 824, 28 CFR 0.100(b), and
Fourth Street Pharmacy v. DEA, 836 F.2d 1137,
1139 (8th Cir. 1988)); see also 21 U.S.C. 823(f)).
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
64131
Respondent did not file exceptions to
the decision.
Having reviewed the entire record, I
have decided to adopt the ALJ’s
recommended rulings, findings of fact,
conclusions of law, and recommended
Order except for her legal conclusions
as to the initial visits of the two
undercover officers (UCs) and her
discussion in the first full paragraph at
page 34 of her slip opinion.1 However,
I need not decide whether the
prescriptions Respondent issued at the
initial visits of the two UCs violated 21
CFR 1306.04(a), because there is
substantial evidence to support the
ALJ’s legal conclusions that he acted
outside of the usual course of
professional practice and lacked a
legitimate medical purpose in issuing
prescriptions at the UCs’ subsequent
visits.
More specifically, one week after the
initial visit of David Hays (UC1), at
which he was prescribed 150 Percocet,
a drug which combines 10 mg of
oxycodone with 325 mg of
acetaminophen, Hays returned to
Respondent complaining that the drug
was causing digestive problems.
Respondent then prescribed 150
Roxicodone (oxycodone) 30 mg, without
any inquiry into Hays’ pain level. Tr. 54,
GX 3a, at 13. Respondent noted in the
chart, however, that Hays ‘‘had no relief
[from] pain.’’ GX 12, at 14.
With respect to this prescription, the
Government’s Expert testified that the
‘‘[m]edication would not have been
indicated given the complaints of the
patient, [and] certainly not that
particular agent and certainly not that
dose or frequency.’’ Tr. 54. Notably, this
1 The ALJ noted that Respondent and his PA
‘‘were given direct evidence of diversion and failed
to act.’’ Slip Op. at 34. More specifically, the ALJ
noted that UC1 had told the PA that his girlfriend
had used some of his controlled substances and that
the PA did nothing in response and that UC2 had
told both Respondent and his PA that he had
bought controlled substances off the street and that
neither Respondent nor his PA took any action. Id.
The ALJ thus reasoned that ‘‘[a] practitioner who
takes no ‘precautions against * * * misuse and
diversion’ exceeds the bound of professional
practice when he prescribes controlled
substances[,]’’ and that ‘‘[s]uch action violates the
standard of diligence expected of a DEA registrant.’’
Id. (quoting United States v. Moore, 423 U.S. 122,
142–43 (1975)).
While purchasing drugs off the street may well be
evidence that a patient is a substance abuser, the
record contains no evidence establishing the
appropriate course of professional practice when a
practitioner is confronted with such information.
Likewise, while UC1’s statement to the PA that his
girlfriend had gotten into his medication supports
a finding that diversion is occurring, here again, the
record contains no evidence establishing what
precautions were required to be taken under the
standard of professional practice. Thus, while I find
this conduct extremely disturbing, I do not rely on
it.
E:\FR\FM\18OCN1.SGM
18OCN1
Agencies
[Federal Register Volume 77, Number 202 (Thursday, October 18, 2012)]
[Notices]
[Pages 64128-64131]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-25576]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Jose Gonzalo Zavaleta, M.D.; Denial of Application
On March 2, 2011, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause (Order) to Jose Gonzalo Zavaleta, M.D. (Applicant), of
Alexandria, Louisiana (La.). The Order proposed the denial of
Applicant's pending applications for DEA Certificates of Registration
as a practitioner, which he filed on April 19, 2010 (Control Number
W10020882C) and on December 9, 2010 (Control Number W10078290C), for
the registered location of 1217 Willow Glen
[[Page 64129]]
River Road, Alexandria, La., on the ground that his registration would
be ``inconsistent with the public interest.'' Order at 1 (citing 21
U.S.C. 823(f)).
The Show Cause Order incorporated by reference the allegations of a
previous Show Cause Order which had been issued on February 23, 2009; a
copy of the latter was attached to the second Show Cause Order. Id. at
1-2. The first Show Cause Order had alleged that Applicant voluntarily
surrendered his DEA Certificate of Registration, BZ5998250, on March
26, 2008, after being charged with six counts of prescribing controlled
substances beyond authority and accepted medical treatment, in
violation of La. Rev. Stat. Ann. Sec. 40:971(C)(1)(2008) (effective
Aug. 15, 2006). Id. The first Order further alleged that Applicant
prescribed controlled substances to undercover agents with ``cursory or
no medical examinations, and without a legitimate medical purpose in
violation of 21 U.S.C. Sec. 841(a)(1),'' including a total of 75
dosage units of hydrocodone (including Lortab and/or Lorcet), which are
schedule III narcotics; 20 dosage units of Xanax, a schedule IV
controlled substance; and six ounces of Phenergan with codeine, a
schedule V narcotic cough syrup. Id. Finally, the first Order alleged
``[Applicant] facilitated the undercover officers' procurement of drugs
by fraudulent means'' when he advised them to ``provide false medical
information'' to justify ``illegitimate prescriptions.'' Id. at 2.
In addition to these allegations, the Second Show Cause Order
alleged that on June 24, 2010, Applicant had entered into a consent
agreement with the Louisiana State Board of Medical Examiners which had
found ``that reasonable cause existed for recommending that a formal
Administrative Complaint be filed against [him], charging [him] with
violation of the Louisiana Medical Practice Act.'' Show Cause Order at
2. The Second Show Cause Order further alleged that ``[t]o avoid the
filing of a formal Administrative Complaint, [Applicant] entered into a
consent order with the Board * * * in which [he] accepted a public
reprimand and various conditions [were] place upon [his] medical
license.''
On March 7, 2011, the Second Show Cause Order, which also notified
Applicant of his right to either request a hearing on the allegations
or to submit a written statement in lieu of a hearing, the procedures
for doing so, and the consequence if he failed to do either, was served
on Applicant by certified mail addressed to him at the address listed
on his second and third applications. Id. at 2 (citing 21 CFR 1316.47;
21 CFR 1301.43). Since service of the Second Order, more than thirty
days have now passed and neither Applicant, nor anyone purporting to
represent him, has either requested a hearing or submitted a written
statement in lieu of a hearing. See 21 CFR 1301.43(b)-(d). Accordingly,
I find that Applicant has waived his rights to a hearing or to submit a
written statement. Id. 1301.43(d). I therefore issue this Decision and
Final Order without a hearing based on relevant material contained in
the investigative record submitted by the Government. I make the
following findings.
Findings
On July 27, 2011, I issued a Decision and Final Order denying
Respondent's application which he filed on July 28, 2008 and which was
the subject of the first Show Cause Order. See Jose Gonzalo Zavaleta,
M.D., 76 FR 49506 (Aug. 10, 2011). Therein, I made extensive findings
that are res judicata in this proceeding.
Applicant was previously the holder of DEA Certificate of
Registration, BZ5998250, which authorized him to dispense controlled
substances in schedules II through V as a practitioner at the
registered location of 5629 Jackson Street Ext., Alexandria, Louisiana.
76 FR 49506. However, on March 26, 2008, concurrent with Applicant's
arrest on state drug charges (the circumstances of which are set forth
below), he voluntarily surrendered his registration. Id. Applicant's
registration was then retired by DEA on March 27, 2008. Id.
On July 28, 2008, Applicant applied for a new DEA registration as a
practitioner in schedules IV and V; this application was denied by my
Order of August 10, 2011. Id. On April 19, 2010, Applicant filed a
second application for a practitioner's registration, seeking authority
to handle controlled substances in schedules II thorugh V at the
registered location of Rapides Primary Health Care Center, 1217 Willow
Glenn River Rd., Alexandria, La. 71302. GX 6, at 1. On his application,
Respondent stated that ``the DA made me an offer for a program called
PTI and no DEA license for two years. Now, I have completed my part of
the deal, meaning I completed two years without [a] DEA license, and
now I want my unrestricted DEA license back.'' Id. On December 9, 2010,
Respondent filed a third application; this application was also for the
registered location of the Rapides Primary Health Care Center. GX 7.
Applicant first came to the attention of law enforcement on January
17, 2008, when Louisiana State Police received a call from a pharmacist
that he had authorized prescriptions for ``excessive amounts of name
brand narcotics with no generic substitutions allowed.'' 76 FR at
49506. Upon receipt of this information, an undercover state trooper
(UC1) visited Applicant's clinic with audio/video recording equipment
on January 23, 2008. Id. When Applicant asked UC1 ``why he was there,''
UC1 responded by requesting ``[h]ydrocodone pain pills.'' Id. UC1
``initially denied that he was in pain but, after negotiating with
[Applicant], he agreed to falsely state that he was suffering from a
sexually transmitted disease,'' and Applicant recorded this false
information in UC1's medical file. Id. Then, Applicant, without any
physical examination to verify the claim of illness or symptoms, wrote
prescriptions for 15 Lortab \1\ pills and an antibiotic. Id. The
undercover agent paid $100 for the visit. Id.
---------------------------------------------------------------------------
\1\ Lortab, which is a combination drug containing hydrocodone
and acetaminophen, is a schedule III controlled substance. 21 CFR
1308.13(e)(iv).
---------------------------------------------------------------------------
Five days later, on January 28, 2008, UC1 returned to Applicant's
clinic seeking additional ``pain pills.'' Id. However, Applicant denied
his request for more pain pills ``because `big brother' was watching
him.'' Id.
Thereafter, on January 30, February 8, and February 28, 2008, a
second state trooper (UC2) visited Applicant's clinic in an undercover
capacity, while equipped with an audio/video recording device. Id. At
UC2's first visit, Applicant issued her a prescription for
hydrocodone,\2\ notwithstanding UC2's ``initially den[ying] she was in
pain'' and ``later stat[ing] she was in pain in order to obtain a
prescription for hydrocodone.'' Id. At her second visit on February 8,
Applicant provided prescriptions for hydrocodone and Phenergan with
codeine,\3\ the latter being a cough syrup, ``even though she had no
cough or congestion and exhibited no such symptoms.'' Id. On UC2's
third visit, she requested and obtained from Applicant prescriptions
for hydrocodone and Xanax.\4\ Id. To justify issuing the prescriptions,
Applicant ``coached'' UC2 about what to say and recorded the coached
statements in her medical file. Id. At the
[[Page 64130]]
undercover visits, Applicant never ``require[d] any medical records nor
did he conduct any physical examinations.'' Id.
---------------------------------------------------------------------------
\2\ Hydrocodone is typically combined with acetaminophen. In
this formulation, it is a schedule III controlled substance. 21 CFR
1308.13(e)(iv).
\3\ Phenergan with codeine cough syrup consists of a combination
of promethazine and codeine; it is a schedule V controlled
substance. 21 CFR 1308.15(c).
\4\ Xanax (alprazolam) is a schedule IV controlled substance. 21
CFR 1308.14(c)(1).
---------------------------------------------------------------------------
On March 20, 2008, after a state court judge issued a warrant for
Applicant's arrest, Louisiana State Police alerted DEA to the
investigation and pending arrest. Id. Thereafter, on March 26, 2008,
Applicant was arrested and charged with ``six counts of prescribing
beyond authority and accepted medical treatment, a violation of
Louisiana Revised Statute 40:971C(1).'' Id. Based on Applicant's
arrest, a DEA Diversion Investigator asked for the voluntary surrender
of his DEA registration; Applicant agreed and signed a DEA-104,
Voluntary Surrender of Controlled Substance Privileges.\5\ Id. at
49506-07.
---------------------------------------------------------------------------
\5\ As part of the record in this matter, the Government
submitted a copy of the Consent Order applicant entered into with
the Louisiana State Board of Medical Examiners. GX 5. While therein,
Applicant ``acknowledge[d] that the reported information could
provide the Investigating Officer with probable cause to pursue
formal administrative proceedings against him for violation of the
[Louisiana Medical Practice] Act,'' Applicant did not admit to any
of the allegations. Id. at 2. Accordingly, I do not rely on the
Consent Order to make any findings regarding violations of federal
law by the Applicant in prescribing to undercover agents.
However, I find that Respondent had a full and fair opportunity
to litigate the allegations of the first DEA Show Cause Order, even
if he did not avail himself of it. See Alan H. Olefsky, 76 FR 20025,
20031 (2011); Robert L. Dougherty 76 FR 16823, 16830 (2011).
Accordingly, those findings are res judicata in this proceeding.
Olefsky, 76 FR at 20031; Dougherty, 76 FR at 16830.
---------------------------------------------------------------------------
Respondent has presented no evidence that he acknowledges his
misconduct and accepts responsibility for it.
Discussion
Section 303(f) of the Controlled Substances Act (CSA) provides that
an application for a practitioner's registration may be denied upon a
determination ``that the issuance of such registration would be
inconsistent with the public interest.'' 21 U.S.C. 823(f). In making
the public interest determination in the case of a practitioner,
Congress directed that the following factors be considered:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The applicant's experience in dispensing * * * controlled
substances.
(3) The applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id.
``[T]hese factors are considered in the disjunctive.'' Robert A.
Leslie, 68 FR 15227, 15230 (2003). I may rely on any one or a
combination of factors and may give each factor the weight I deem
appropriate in determining whether * * * to deny an application. Id.
Moreover, I am ``not required to make findings as to all of the
factors.'' Hoxie v. DEA, 419 F.3d 477, 482 (6th Cir. 2005) (citing
Morall v. DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005)).
In this matter, while I have considered all of the factors, I
conclude that it is not necessary to make findings with respect to
factors one (the recommendation of the state licensing board), three
(applicant's conviction record) and five (such other conduct which may
threaten public health and safety). Having previously found that
Applicant has committed acts which render his registration
``inconsistent with the public interest,'' 76 FR at 49507 (quoting 21
U.S.C. 823(f), 824(a)(4)), and Applicant having failed to present any
evidence to rebut this conclusion, I will order that his pending
applications for registration be denied.
Factors Two and Four--Applicant's Experience in Dispensing Controlled
Substances and Compliance With Applicable Laws Related to Controlled
Substances
Under a longstanding DEA regulation, a prescription for a
controlled substance is not ``effective'' unless it is ``issued for a
legitimate medical purpose by an individual practitioner acting in the
usual course of his professional practice.'' 21 CFR 1306.04(a). This
regulation further provides that ``an order purporting to be a
prescription issued not in the usual course of professional treatment *
* * is not a prescription within the meaning and intent of [21 U.S.C.
829] and * * * the person issuing it, shall be subject to the penalties
provided for violations of the provisions of law related to controlled
substances.'' Id.; see also La. Rev. Stat. Ann. Sec. 40:961(33) (2008)
(effective Aug. 15, 2004); \6\ La. Rev. Stat. Ann. Sec. 40:1238.2(A)
(2008) (effective Aug. 15, 2006).\7\
---------------------------------------------------------------------------
\6\ Louisiana law defines the term ``prescription'' to mean ``a
written request for a drug * * * issued by a licensed physician * *
* for a legitimate medical purpose, for the purpose of correcting a
physical, mental, or bodily ailment, and acting in good faith in the
usual course of his professional practice.'' La. Rev. Stat. Ann.
Sec. 40.961(33).
\7\ This statute provides that:
A prescription, in order to be effective in legalizing the
possession of legend drugs, shall be issued for a legitimate medical
purpose by one authorized to prescribe the use of such legend drugs.
An order purporting to be a prescription issued to a drug abuser or
habitual user of legend drugs, not in the course of professional
treatment, is not a prescription within the meaning and intent of
this Section. Any person who knows or should know that he or she is
filling such a prescription or order to a drug abuser or habitual
user of legend drugs, as well as the person issuing the
prescription, may be charged with a violation of this Section.
La. Rev. Stat. Ann. Sec. 40:1238.2(A).
---------------------------------------------------------------------------
As the Supreme Court recently explained, ``the [CSA's] prescription
requirement * * * ensures patients use controlled substances under the
supervision of a doctor so as to prevent addiction and recreational
abuse. As a corollary, [it] also bars doctors from peddling to patients
who crave the drugs for those prohibited uses.'' Gonzales v. Oregon,
546 U.S. 243, 274 (2006) (citing United States v. Moore, 423 U.S. 122,
135, 143 (1975)); see also La. Rev. Stat. Ann. Sec. 40:1238.2(A)
(2008) (effective Aug. 15, 2006).
Under the CSA, it is fundamental that a practitioner must establish
and maintain a bonafide doctor-patient relationship in order to act
``in the usual course of * * * professional practice'' and to issue a
prescription for a ``legitimate medical purpose.'' Laurence T.
McKinney, 73 FR 43260, 43265 n.22 (2008); see also Moore, 423 U.S. at
142-43 (noting that evidence established that physician ``exceeded the
bounds of `professional practice,''' when ``he gave inadequate physical
examinations or none at all,'' ``ignored the results of the tests he
did make,'' and ``took no precautions against * * * misuse and
diversion''). The CSA generally looks to state law to determine whether
a doctor and patient have established a bonafide doctor-patient
relationship. See Kamir Garces-Mejias, 72 FR 54931, 54935 (2007);
United Prescription Services, Inc., 72 FR 50397, 50407 (2007); but see
21 U.S.C. Sec. 829(e)(2)(B) (providing federal standard for
prescribing over the internet).
Under the regulation of the Louisiana Board of Medical Examiners,
in the treatment of ``intractable pain * * * a physician shall comply''
with the Louisiana Pain Rules, including the requirements that a
physician perform an ``[e]valuation of the [p]atient'' and make a
``[m]edical [d]iagnosis.'' La. Admin. Code tit. 46:XLV.6921(A) (2008).
``Evaluation of the patient shall initially include relevant medical,
pain, alcohol and substance abuse histories, an assessment of the
impact of pain on the patient's physical and psychological functions, a
review of previous diagnostics studies, previously utilized therapies,
an assessment of coexisting illnesses, diseases, or conditions, and an
appropriate physical examination.'' Id.
[[Page 64131]]
(emphasis added); see also Armstrong v. La. State Bd. of Med.
Examiners, 868 So. 2d 830, 840 (La.App. 4 Cir. Feb. 18, 2004)
(upholding two year suspension of physician's license; noting that when
prescribing controlled substances for relief of non-malignant pain is
``unaccompanied by appropriate testing, diagnosis, oversight and
monitoring * * * the physician falls below generally accepted standards
of care''); Pastorek v. La. State Bd. of Med. Examiners, 4 So. 3d 833
(La.App. 4 Cir. Dec. 17, 2008). The Board's rules further require that
a ``medical diagnosis * * * be established and fully documented in the
patient's medical record.'' La. Admin. Code tit. 46:XLV.6921(A)(2)
(2008).
Louisiana law also prohibits a physician from ``[a]ssist[ing] a
patient or any other person in obtaining a controlled dangerous
substance through misrepresentation, fraud, forgery, deception, or
subterfuge.'' La. Rev. Stat. Ann. Sec. 40:971.2 (2008) (effective Aug.
15, 2005). It is also unlawful for a physician to ``prescribe * * *
legally controlled substances beyond his respective prescribing
authority or for a purpose other than accepted medical treatment of
disease, condition, or illness. Id., at Sec. 40:971(C)(1) (2008)
(effective Sept. 9, 1988).
As found in my Decision and Order of July 27, 2011, on four
occasions, Applicant prescribed drugs containing hydrocodone (including
Lortab and/or Lorcet), which are schedule III narcotics; Xanax, a
schedule IV controlled substance; and Phenergan with codeine, a
schedule V narcotic cough syrup; to Louisiana State Troopers acting in
undercover capacities. See 76 FR at 49508. Notably, Applicant issued
these prescriptions without conducting a physical examination at any of
the visits and the undercover agents received these prescriptions even
though they did not demonstrate conditions or symptoms that would
justify the prescriptions. Id.
Moreover, both undercover agents initially denied they were in
pain, but Applicant assisted the agents in obtaining controlled
substances by encouraging them to make false statements. See id. For
example, while he denied being in pain, UC1 asked Applicant for
``[h]ydrocodone pain pills,'' and then ``negotiate[ed]'' with Applicant
to ``falsely state'' he had a sexually transmitted disease. Id.
Likewise, Applicant also ``coached'' the second undercover agent on
what to say to ``justify issuing the prescriptions and wrote her
coached statements in a medical file.'' Id. Therefore, Applicant failed
to establish a physician-patient relationship, lacked a legitimate
medical purpose, and acted outside of the usual course of professional
practice in prescribing controlled substances to the undercover agents
and thus violated Federal law. See id. (citing 21 CFR 1306.04(a); 21
U.S.C. 841(a)(1); see also Louisiana v. Moody, 393 So. 2d 1212, 1215
(La. 1981) (holding that physician furnished prescriptions for ``other
than a legitimate medical purpose'' based on evidence showing that
prescriptions were issued in response to specific requests of patients
and physician did not conduct physical examinations or take medical
histories)).
I therefore hold again that granting Applicant's applications for a
new registration ``would be inconsistent with the public interest.\8\''
21 U.S.C. 823(f). Accordingly, I will order that Applicant's pending
applications be denied.
---------------------------------------------------------------------------
\8\ As found above, Applicant stated in his second application
that ``the DA made me an offer for a program called PTI and no DEA
license for two years,'' and that because he has ``completed two
years without [a] DEA license,'' he ``want[s] [his] unrestricted DEA
license back.'' GX 6. Respondent has presented no evidence that any
DEA official agreed to the deal he made with the district attorney,
and in any event, a state official has no authority to bind this
Agency. See Edmund Chein, 72 FR 6580, 6590 (2007) (Congress granted
the authority to determine whether a registration ``is consistent
with the public interest'' to ``the Attorney General of the United
States, and that authority has been delegated solely to the
officials of [DEA]. State officials therefore lack authority to
resolve a matter pending before the Drug Enforcement
Administration'' and cannot bind this Agency.) (citing 21 U.S.C.
824, 28 CFR 0.100(b), and Fourth Street Pharmacy v. DEA, 836 F.2d
1137, 1139 (8th Cir. 1988)); see also 21 U.S.C. 823(f)).
---------------------------------------------------------------------------
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 28
CFR 0.100(b), I order that the applications (Control Numbers W10020882C
and W10078290C) of Jose Gonzalo Zavaleta, M.D., for a DEA Certificate
of Registration as a practitioner be, and they hereby are, denied. This
order is effective November 19, 2012.
Dated: October 8, 2012.
Michele M. Leonhart,
Administrator.
[FR Doc. 2012-25576 Filed 10-17-12; 8:45 am]
BILLING CODE 4410-09-P